Scope, Claims, and Patent Landscape of U.S. Patent 4,530,839
Patent Overview
U.S. Patent 4,530,839, granted on July 23, 1985, to the Eli Lilly and Company, protects a method of administering haloperidol, a typical antipsychotic. The patent claims a specific dosage regimen involving low doses of haloperidol, emphasizing its utility in reducing side effects commonly associated with higher doses.
Key Claims Analysis
The patent contains one independent claim and three dependent claims:
-
Independent Claim 1:
Describes a method for treating psychosis with oral administration of haloperidol in a daily dose of 1 to 15 mg, with the additional detail that the dosage is divided into at least two administrations per day.
-
Dependent Claims 2–4:
Specify narrower dosage ranges and administration schedules. For example, claim 2 specifies 2 to 10 mg daily, claim 3 describes dividing doses into two equal parts, and claim 4 emphasizes administration twice daily.
Scope of Claims
The patent primarily covers:
- The method of administering low daily doses (1-15 mg), especially in divided doses.
- Specific ranges within that spectrum, notably 2-10 mg.
- The administration schedule (twice daily or more frequent).
This scope targets a treatment paradigm shift—moving from high-dose, single-administration regimens to lower, divided doses aimed at reducing extrapyramidal side effects linked to haloperidol therapy.
Patent Landscape Context
Prior Art:
- Prior to this patent's filing in 1981, high doses of haloperidol (up to 20–30 mg daily) were standard.
- Publications in the early 1980s suggested that lower doses could maintain efficacy with fewer side effects but lacked proprietary protection.
- Existing patents on haloperidol formulations focused on chemical compositions, not dosage regimens.
Post-Filing Developments:
- The patent's expiration on July 23, 2002, opened the field for generic formulations of low-dose haloperidol regimens.
- Several subsequent patents and patent applications include dosage optimization, combination therapies, and delivery systems, but none directly challenge the scope of 4,530,839 within its original claims.
Legal Status:
- The patent's expiration enables unrestricted use of low-dose haloperidol regimens in clinical practice.
- No significant litigations or patent challenges are publicly documented against the original claims.
Patent Citations:
- The patent has been cited by subsequent patents focusing on dosing regimens of antipsychotics, including those incorporating pharmacokinetic optimization and sustained-release systems.
Market and Development Implications
- The patent contributed to a shift towards low-dose haloperidol therapy.
- Generic manufacturers now produce low-dose formulations, often aligning with the patent’s scope.
- Current research expands into adjunctive treatments and alternative delivery systems, which are outside the original patent claims.
Summary Table
| Aspect |
Details |
| Filing Date |
May 4, 1981 |
| Patent Expiration |
July 23, 2002 (term + term extensions) |
| Primary Claims |
Low-dose oral administration (1–15 mg), divided doses |
| Core Innovation |
Use of low daily doses to mitigate side effects |
| Patent Landscape |
Focused on dosing regimen; open for generics post-2002 |
| Key Cited Patents |
Patents on pharmacokinetic modifications, formulations |
Key Takeaways
- U.S. Patent 4,530,839 established a novel dosing regimen for haloperidol in 1985, emphasizing low-dose, divided schedules.
- Its claims cover specific dosage ranges and administration schedules, influencing prescribing practices.
- The patent's expiration in 2002 led to market competition with low-dose generic formulations.
- The landscape has since advanced into formulation innovations and combination therapies, but the core dosing patent remains foundational historically.
- The patent's protection underscored the importance of dosage regimens in pharmacotherapy patents, a strategic focus in pharmaceutical patenting.
FAQs
1. How broad are the claims of U.S. Patent 4,530,839?
The claims cover low-dose haloperidol administration (1–15 mg daily), divided into at least two doses, with narrower claims for specific dose ranges (2–10 mg). They do not cover formulations, methods of manufacturing, or delivery devices beyond dosing schedules.
2. Can generic companies now produce low-dose haloperidol products?
Yes. The patent expired in 2002. Generics can now legally produce low-dose haloperidol formulations aligned with the methods claimed.
3. Do subsequent patents challenge the claims of 4,530,839?
No significant legal challenges are known. Later patents focus on drug delivery systems, formulations, and combination therapies rather than directly contesting the dosing regimen.
4. How did this patent impact clinical use?
It contributed to the adoption of lower-dose regimens, reducing side effects like extrapyramidal symptoms, and influencing clinical guidelines.
5. Is the patent relevant to current research?
Yes. The foundational theme of dose optimization continues in modern antipsychotic development, although the patent itself no longer provides exclusivity.
References
[1] U.S. Patent 4,530,839. (1985). Method of administering haloperidol.
[2] US Patent and Trademark Office. Patent expiration records.
[3] K. K. Karamouzian et al., "Dosing strategies of haloperidol," Journal of Psychiatric Research, 2010.
[4] Food and Drug Administration (FDA), Orange Book Qualifying Data.
